Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Medanta, The Medicity, India
- Target Recruit Count
- 200
- Registration Number
- NCT06095492
- Locations
- 🇮🇳
Division Of Endocrinology & Diabetes, Medanta The Medicity, Gurgaon, Haryana, India
Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- EMS
- Target Recruit Count
- 597
- Registration Number
- NCT05886088
- Locations
- 🇧🇷
Investigational site, Hortolândia, SP, Brazil
Cognitive Protective Effect of Newer Antidiabetic Drugs
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT05347459
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-10-17
- Target Recruit Count
- 324
- Registration Number
- NCT05313529
- Locations
- 🇨🇳
Department of Endocrinology, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
🇨🇳Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
🇨🇳Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
Effects of DPP4 Inhibition on COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- University of Miami
- Registration Number
- NCT04341935
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 85
- Registration Number
- NCT04180813
- Locations
- 🇨🇳
Huai'an first people's hospital, Huai'an, China
🇨🇳Dongying People's Hospital, Dongying, China
🇨🇳Zhongda Hospital Southeast University, Nanjing, China
Replication of the CARMELINA Diabetes Trial in Healthcare Claims
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 101830
- Registration Number
- NCT03936036
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.
- Conditions
- Interventions
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 209
- Registration Number
- NCT03667300
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Empagliflozin in NODAT
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT03642184
- Locations
- 🇨🇳
Department of nephrology, endocrinology and kidney transplantation , Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.